| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Nov 8, 2022Initiated our Phase 2 clinical trial for the potential treatment of familial adenomatous polyposis (FAP) Initiated our Phase 1 clinical trial for the potential treatment of Clostridium difficile...
-
Nov 2, 2022
Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following investor conferences:...
-
Oct 25, 2022Recursion Announces $150 Million Private Placement to New and Existing Investors, led by Kinnevik AB
Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, announced today that it has entered into a stock purchase agreement for the...
-
Sep 13, 2022
Recursion initiates TUPELO, a Phase 2 trial of REC-4881 for the potential treatment of Familial Adenomatous Polyposis (FAP) Recursion initiates a Phase 1 trial for the potential treatment of...
-
Sep 1, 2022
Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following investor conferences:...
Aug 18, 2022Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that it recently received a Prime Rating for ESG performance...
Aug 9, 2022Actively enrolling participants in our Phase 2/3 clinical trial for the potential treatment of progressive NF2-mutated meningiomas On track to initiate our Phase 2 clinical trial for the potential...
-
Aug 2, 2022
Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following investor conference:...
-
Jul 21, 2022
Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that the European Commission has granted Recursion Orphan...
Jun 20, 2022If successful, REC-2282 could be the first approved treatment for NF2-mutated meningiomas, which are debilitating lesions that occur in approximately 33,000 patients per year REC-2282 has been...
-
Jun 2, 2022
Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following upcoming investor conferences:
May 10, 2022Enrolled the first participant in our Phase 2 clinical trial for CCM and dosed multiple participants Expecting to enroll the first participant in our Phase 2/3 clinical trial for progressive...
-
May 2, 2022
Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following upcoming investor...
-
Apr 11, 2022
Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that the U.S. Food and Drug Administration (FDA) has granted...
-
Mar 31, 2022
Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following upcoming investor conferences:
-
Mar 30, 2022
The total capital represents the largest seed financing for life science startups in Utah's history SALT LAKE CITY, March 30, 2022 /PRNewswire/ -- Altitude Lab today announced its first cohort of...
-
Mar 24, 2022
Releases inaugural report less than one year after becoming a publicly-traded company, demonstrating its strong commitment to ESG stewardship Announces new long-term commitments focused on...
Mar 23, 2022Announced a transformational collaboration with Roche and Genentech to build and navigate maps of biology in neuroscience and an indication in gastrointestinal oncology and to advance up to 40...
-
Mar 18, 2022
Recursion's small molecule is the first therapeutic candidate to be advanced to an industry-sponsored clinical trial for cerebral cavernous malformation (CCM) CCM is a devastating neurovascular...
-
Mar 3, 2022
Recursion (NASDAQ: RXRX) today provided updated guidance on clinical trial starts: Recursion's leadership team has decided that conducting a dose optimization study in a sheep efficacy model of...
-
Mar 2, 2022
Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following upcoming investor conferences:
-
Feb 8, 2022
Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following upcoming investor conferences:
-
Dec 7, 2021The deal, worth several billion dollars, is a future-looking model of technology-enabled target and drug discovery
Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery, development and beyond through disruptive...
-
Dec 6, 2021Use of latest Recursion inference technologies to expand exploration of fibrosis and may extend the collaboration to more than a dozen programs in total
Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery, development and beyond through disruptive...
-
Nov 30, 2021Appointments will support continued expansion in neuroscience and acceleration of inferential search capabilities
Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery, development and beyond through disruptive...
Nov 10, 2021- Received Fast Track Designation for REC-2282, a potential treatment for NF2 meningiomas, and expect to enroll the first patient in a Phase 2/3 trial in early 2022Recursion (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering,...
-
Oct 7, 2021
Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering,...
-
Sep 29, 2021
Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering,...
-
Aug 16, 2021Christensen to lead Recursion's Toronto office, opening in 2021
Recursion, a digital biology company industrializing drug discovery, today announced the appointment of Jordan Christensen as its Vice President of Engineering. In addition to leading all of...
Aug 13, 2021- Expanded the total number of research and development programs from 37 to 48Recursion (Nasdaq: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering,...
-
Jul 13, 2021Therapeutics Advisory Board to help guide Recursion's growing clinical pipeline through development
Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering,...
Jul 12, 2021Recursion and Bright Horizons partner to open child care center in Gateway Mall, next to Recursion's Salt Lake City headquartersRecursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering,...
-
Jul 1, 2021
Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering,...
-
Jun 23, 2021
Recursion to open office space within Mila and build machine learning team to focus on some of drug discovery's most challenging problems MONTRÉAL, June 23, 2021 /PRNewswire/ -- Recursion...
-
Jun 15, 2021
The company aims to hire up to 50 people by the end of 2021 across disciplines of data science, machine learning, engineering, product management and computational biology. TORONTO, June 15, 2021...
-
Jun 8, 2021Lux Capital, Mubadala Capital, Obvious Ventures, and DCVC among founding group supporting underrepresented founders building next-generation healthcare companies
Altitude Lab today announced the launch of its Investor Coalition, a partnered network of leading healthcare venture capitalists to fund, mentor, and provide resources for Altitude-incubated...
-
May 25, 2021
Recursion Pharmaceuticals, Inc. (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine...
-
May 12, 2021- Strengthened balance sheet with the completion of a successful IPO
Recursion Pharmaceuticals, Inc. (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data...
-
Apr 21, 2021
Recursion Pharmaceuticals, Inc. ("Recursion" or "we") announced the closing on April 20, 2021 of its initial public offering of 27,878,787 shares of its Class A common stock, which includes the...
-
Apr 16, 2021
Recursion Pharmaceuticals, Inc. ("Recursion" or "we") today announced the pricing of its initial public offering of its Class A common stock at a price to the public of $18.00 per share. Recursion...
-
Mar 1, 2021Former Goldman Sachs executive to serve as Chairman of Recursion's Board, effective immediately
Recursion, a digital biology company industrializing drug discovery, today announced the appointment of R. Martin Chavez as Chairman of its Board of Directors. Dr. Chavez, who joined Recursion's...
-
Feb 18, 2021Former VP & Assistant General Counsel at Pfizer to join Recursion's executive team
Recursion, a biotechnology company scaling more like a technology company, today announced the appointment of Louisa Daniels, J.D., MBA as its Chief Legal Officer and General Counsel. In her new...
-
Jan 8, 2021Former Chief Medical Officer of Blade Therapeutics and Genentech Group Medical Director to lead Recursion’s clinical development programs
SALT LAKE CITY--(BUSINESS WIRE)--Recursion, a digital biology company industrializing drug discovery, today announced the appointment of Dr. Ramona Doyle as its Chief Medical Officer. Dr. Doyle...
-
Sep 9, 2020- Drug discovery partnership and equity investment led by Leaps by Bayer in Series D financing round
Berlin, Germany and Salt Lake City, USA, September 9, 2020 – Bayer and US-based Recursion Pharmaceuticals, Inc., a digital biology company industrializing drug discovery, have entered into a...
-
Sep 9, 2020− Proceeds to support Recursion’s development of its broad clinical-stage pipeline and expansion of the capabilities of its drug discovery platform −
SALT LAKE CITY, September 9, 2020 — Recursion, a digital biology company industrializing drug discovery, today announced a $239 million oversubscribed Series D financing. The financing was led...
-
Jul 28, 2020
SALT LAKE CITY--(BUSINESS WIRE)--Recursion, a digital biology™ company leading in the industrialization of drug discovery, today announced its acquisition of Vium, a digital vivarium™ company....
-
Jun 25, 2020More than 305,000 high-resolution, multi-channel COVID-19 cellular images captured in less than four weeks with Molecular Devices ImageXpress® Micro Confocal High-Content Imaging System are now available to the scientific community.
SAN JOSE, Calif. – June 25, 2020 — With the COVID-19 pandemic impacting millions around the globe, researchers are racing to develop a vaccine or drug treatment. In an effort to better...
-
Nov 8, 2018
Recursion Pharmaceuticals, a biotechnology company that combines artificial intelligence (AI), experimental biology, and automation to discover and develop drugs at scale, today announced a $1.6...
-
Nov 5, 2018Award coincides with the opening of Recursion's expansive new R&D facility
Recursion Pharmaceuticals, a biotechnology company that combines artificial intelligence (AI), experimental biology, and automation to discover and develop drugs at scale, has been awarded a 2018...
-
Jul 10, 2018
Recursion, a biotechnology company that combines artificial intelligence (AI), experimental biology, and automation to discover drugs at scale, today announced that the U.S. Food and Drug...
-
Jul 10, 2018
Recursion, a biotechnology company that combines artificial intelligence (AI), experimental biology, and automation to discover and develop drugs at scale, today announced the company has...
-
May 15, 2018
Recursion Pharmaceuticals, a biotechnology company that combines artificial intelligence (AI), experimental biology, and automation to discover drugs at scale, today announced that it has hired...
-
May 7, 2018The grant, awarded by the Bill & Melinda Gates Foundation, represents a collaborative effort between Recursion and the Winzeler Lab at UC San Diego School of Medicine to accelerate the discovery of drugs to treat malaria, and sets the stage for Recursion to further broaden its drug discovery platform into infectious disease.
Recursion Pharmaceuticals today announced the award of a $546,000 grant from the Bill & Melinda Gates Foundation to apply Recursion's AI-enabled technology to the discovery of novel drugs with the...
-
May 1, 2018Pharmaceutical Business Development Leader Dr. Kevin Lynch Joins Recursion as Chief Business Officer
Recursion Pharmaceuticals, a biotechnology company that combines artificial intelligence (AI), experimental biology, and automation to discover drugs at scale, today announced it has hired Kevin...
-
Jun 28, 2017Former Bristol-Myers Squibb scientist and regulatory affairs expert joins Recursion
Recursion Pharmaceuticals, an emerging biotechnology company today announced it has hired Dr. Chand Sishta as the senior director of regulatory affairs. Chand joins the company after 25 years in...
-
Apr 28, 2017Bengio to advise on Recursion's unique approach to discovering new therapies for rare genetic diseases at the intersection of deep learning and biology
Recursion Pharmaceuticals, an emerging biotechnology company that combines innovative biological science with machine learning techniques to discover treatments for rare genetic diseases, today...
-
Apr 18, 2017Former Johnson & Johnson scientist will expand Recursion's drug discovery capabilities
Recursion Pharmaceuticals, an emerging biotechnology company that combines innovative biological science with machine learning techniques to discover treatments for rare genetic diseases, today...